department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

UGN-104 · pharmadog

pharmadog
drugs
UGN-104

drug · small molecule

patient view →

UGN-104

Phase 3updated 2mo ago

by $URGN UroGen Pharma Ltd.🔗 ChEMBL

Phase 3

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 32 investigational indications.

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

trade names

Jelmyto, Mitomycin, Mitosol, Mitozytrex, Mutamycin, Mytozytrex

generic

mitomycin

indication

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

phase

phase_3

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 7

drugJelmyto1 co-mentions · 1 sources
companyAll India Institute of Medical Sciences1 co-mentions · 1 sources
companyAll India Institute of Medical Sciences Bathinda1 co-mentions · 1 sources
tagOphthalmology1 co-mentions · 1 sources
drugUGN-1031 co-mentions · 1 sources
drugmitomycin1 co-mentions · 1 sources
drugmitomycin SR1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying UGN-104

phase3Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)active not recruitingn=520
phase3A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)active not recruitingn=272
phase3A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancerrecruitingn=220
phase2A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)completedn=107
phase3A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCnot yet recruitingn=236
N/AAdaptive Radiation in Anal Cancerrecruitingn=20
phase3A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancerrecruitingn=70
phase4Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancerrecruitingn=272

more trials →